Cihan Ay and Colleagues on Large Language Models VS Thrombosis Experts
International Society on Thrombosis and Haemostasis (ISTH) shared on LinkedIn:
”AI meets thrombosis expertise
A new international study led in part by Cihan Ay, ISTH member and researcher at Medical University of Vienna, reveals that artificial intelligence (AI) language models can sometimes provide better answers than experts when educating patients about venous thromboembolism (VTE).
In complex clinical decision-making, the study found that AI recommendations were often on par with thrombosis specialists, a promising insight into the future of medical education and support tools.
Published in the Journal of Thrombosis and Haemostasis (JTH), the leading journal of the ISTH.
Learn more here.
Read the article here.”
Read the full article in JTH.
Article: Large language models versus thrombosis experts: A comparative study on patient education and clinical decision-making in venous thromboembolism
Authors: Nikola Vladic, Stephan Nopp, Ingrid Pabinger, Walter Ageno, Jean M. Connors, Sabine Eichinger, Cihan Ay, on behalf of the ClotGPT study group

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia
